Montelukast

Montelukast (Singulair) is a cysteinyl leukotriene receptor antagonist — it blocks the CysLT1 receptor, preventing Leukotrienes (LTC4, LTD4, LTE4) from binding and producing their downstream effects.

What It Targets

The 5-LOX branch of Arachidonic Acid metabolism produces cysteinyl leukotrienes, which are 100-1000x more potent than Histamine at causing bronchoconstriction and are significant drivers of vascular permeability, mucus production, and eosinophil recruitment.

Montelukast blocks the receptor these leukotrienes act on. It does NOT block Histamine receptors — it targets a completely different mediator pathway. This is why it’s additive to H1 Antihistamines and H2 Antihistamines rather than redundant.

When It Helps

Particularly useful when:

• Respiratory symptoms persist despite antihistamine therapy
• Salicylate sensitivity suggests leukotriene-predominant pathology
• Urinary LTE4 is elevated (direct evidence of leukotriene overproduction)
• Symptoms include significant bronchoconstriction, nasal congestion, or persistent swelling

The Neuropsychiatric Warning

FDA Black Box Warning

Montelukast carries an FDA black box warning for neuropsychiatric side effects: agitation, aggression, anxiety, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, suicidal thinking and behavior, and tremor. The mechanism is not fully understood. These effects are uncommon but can be serious.

Monitoring is important, especially in the first weeks. If neuropsychiatric symptoms emerge, discontinuation should be discussed with the prescribing provider. For some patients the mast cell benefits justify the risk; for others it’s not tolerable.